Table 3.
Antibodies to PLA2R in patients with relapse
| Case no. | Age /sex | Primary therapy | aPLA2R (RU/ml) (baseline) |
aPLA2R (RU/ml) (6 mo) |
aPLA2R (RU/ml) (12 mo) |
aPLA2R (RU/ml) (relapse) |
|---|---|---|---|---|---|---|
| 1 | 48/F | TAC/GCs | 337.16 | 3.32 | 4.51 | 221.71 |
| 2 | 60/F | TAC/GCs | 214.13 | 1.25 | 1.41 | 322.37 |
| 3 | 41/M | TAC/GCs | 203.46 | 4.24 | 4.28 | 186.67 |
| 4 | 42/M | TAC/GCs | 159.50 | 1.30 | 1.25 | 294.73 |
| 5 | 40/M | TAC/GCs | 117.47 | 6.26 | 0.45 | NA |
| 6 | 38/M | TAC/GCs | 89.15 | 2.06 | 0.45 | 56.68 |
| 7 | 36/M | TAC/GCs | 84.22 | 15.04 | 6.20 | 23.26 |
| 8 | 48/M | TAC/GCs | 50.55 | 36.30 | 0.45 | 135.90 |
| 9 | 45/F | TAC/GCs | 21.41 | 15.04 | 2.04 | 32.52 |
| 10 | 53/M | cCTX/GCs | 1016.78 | 4.51 | 5.18 | 0.01 (negative) |
| 11 | 24/M | cCTX/GCs | 525.25 | 10.79 | 9.21 | 46.58 |
| 12 | 45/M | TAC/GCs | 221.81 | 1.36 | 0.45 | 82.92 |
aPLA2R > 20 RU/ml were considered positive.
aPLA2R, Antibodies to m-type phospholipase A2 receptor; cCTX, cyclical cyclophosphamide; F, female; GCs, glucocorticoids; M, male; NA, not available; RU, resonance unit; TAC, tacrolimus.